Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-CMV Guided Secondary Prophylaxis in SOT Patients
NCT02370758Completed
- Sponsor
- University Health Network
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label trial of valganciclovir and ganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by University Health Network. Primary endpoint: Virologic recurrence or disease recurrence at 6 months. Started Nov 2014; status: completed.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02370758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370758.